New non-invasive method for selecting embryos in IVF
A Novel Integrative Non-invasive Embryo Selection Approach for in Vitro Fertilization Based on Artificial Intelligence Enhanced Morphokinetic Analysis and Raman Spectra in Spent Culture Media
This study is testing a new non-invasive way to choose the best embryos during IVF to see if it can help more people get pregnant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 176 (estimated) |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05896709 on ClinicalTrials.gov |
What this trial studies
This study aims to improve embryo selection during in vitro fertilization (IVF) by using a novel non-invasive approach that combines morphokinetic analysis with Raman spectroscopy. In the first phase, archived data will be analyzed to train a convolutional neural network (CNN) for embryo selection. The second phase will involve a randomized controlled trial to assess the effectiveness of this integrated method in increasing clinical pregnancy rates. The approach promises to provide a quicker and more cost-effective alternative to traditional invasive genetic testing methods.
Who should consider this trial
Good fit: Ideal candidates include patients undergoing their first, second, or third IVF/ICSI treatment cycle with at least three normal fertilized embryos.
Not a fit: Patients with known genetic diseases or those whose embryos do not meet imaging quality standards may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could significantly enhance the chances of clinical pregnancy for patients undergoing IVF.
How similar studies have performed: Other studies have shown promise in using AI and non-invasive techniques for embryo selection, indicating a growing interest in this innovative approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients undergoing IVF/ ICSI treatment 2. Patients receiving the first, second or third IVF/ICSI treatment cycle 3. Patients and their partners willing to sign the informed consent agreement 4. Patients having at least three normal fertilised embryos on the day of the fertilization check 5. Consecutive women undergoing IVF treatment 6. Patients planning to use a time-lapse incubator for embryo culture Exclusion Criteria: 1. Day one human embryos with blur imaging 2. Large obstructions in the embryo area 3. More than half of the embryo area is blocked by the well or degeneration 4. Patients with more than half of the embryos without sufficient spent culture medium for RS analysis 5. Patients with known genetic diseases
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Pui Wah Jacqueline Chung — Chinese University of Hong Kong
- Study coordinator: Pui Wah Jacqueline Chung
- Email: jacquelinechung@cuhk.edu.hk
- Phone: +852 35051537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.